XMAD
RJF
, Last price
Name
Laboratorio Reig Jofre SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs, over-the-counter (OTC) products, medical devices, and cosmetics. The company's offerings are categorized into several key areas: advanced pharmaceutical technologies, which include antibiotics and injectable formulations; specialized healthcare solutions targeting dermatological, musculoskeletal (joint health and pain), women's health, respiratory/ENT, and pediatric needs; and consumer health items marketed under its Forté Pharma brand. Furthermore, Laboratorio Reig Jofre provides contract development and manufacturing (CDMO) as well as contract manufacturing organization (CMO) services. Founded in 1929 and headquartered in Sant Joan Despí, Spain, the company sells its products directly in seven countries and collaborates with business partners to reach approximately 70 other nations. It operates as a subsidiary of Reig Jofre Investments SL.
Related entities
Parent
REIG JOFRE INVESTMENTS S.L.
Key people
Isabel Reig Lopez
Chairman of the Board, Representative of Reig Jofre Investments SL · since 2015
Roser Gomila Zabala
Chief Financial Officer · since 2017
Gabriel Roig Zapatero
Chief Operating Officer · since 2017
Ignasi Biosca Reig
Chief Executive Officer, Executive Director · since 2015
Antonio Ballesteros Gomez
General Director of RJF Pharma Spain · since 2016
Alain Boutboul
General Director of Forte Pharma · since 2017
Ignacio Vila Rocafort
General Industrial Director
Adolf Rousaud Vinas
Non-Member Secretary of the Board · since 2015
Alejandro Garcia Reig
Vice Chairman of the Board · since 2017
Anton Costas Comesana
Independent Director · since 2015
Maria Luisa Francoli Plaza
Independent Director · since 2015
Ramon Gomis I de Barbara
Independent Director · since 2015
Ramiro Martinez-Pardo del Valle
Independent Director · since 2015
Independent Director · since 2015
Headquarters & legal address
Gran Capità 10
Sant Joan Despí 08970
ES
Sant Joan Despí 08970
ES
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||